Newsroom | 8286 results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), het toonaangevende bedrijf op gebied van RNAi-therapeutica, kondigde vandaag aan dat het bedrijf nieuwe gegevens uit haar hypertensie- en ATTR-programma's (transthyretine-amyloïdose) zal voorstellen tijdens het komende ESC Congress (European Society of Cardiology) 2025, dat doorgaat in Madrid, Spanje, van 29 augustus tot 1 september 2025. Deze voorstellingen zullen het potentieel van RNAi-therapeutica toelichten om...

CAMBRIDGE, Massachusetts--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), la empresa líder en terapias de ARN interferente, anunció hoy que la Empresa presentará nuevos datos de sus programas de hipertensión y amiloidosis por transtiretina (ATTR) en el próximo congreso de la Sociedad Europea de Cardiología 2025, que se llevará a cabo en Madrid (España) del 29 de agosto al 1 de septiembre de 2025. Estas presentaciones destacarán el potencial de las terapias de ARN interferente par...

PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics reports on Second Quarter 2025 financial results and provides corporate update on strategic clinical trial plans....

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present new data from its hypertension and transthyretin amyloidosis (ATTR) programs at the upcoming European Society of Cardiology (ESC) Congress 2025, taking place in Madrid, Spain, from August 29 - September 1, 2025. These presentations will highlight the potential of RNAi therapeutics to transform the treatment of cardiovascular diseas...

DUBLIN--(BUSINESS WIRE)--The "Europe Defibrillator Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ResearchAndMarkets.com's offering. The Europe defibrillator market achieved USD 3.87 billion in 2024 and is expected to expand to USD 7.23 billion by 2033, growing at a CAGR of 7.2% from 2025 to 2033. The market is growing due to the growing prevalence of cardiovascular disease, raising awareness of emergency cardiac care, and technology advan...

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective August 5th, 2025, to three non-executive employees of non-qualified stock...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, at 4:30 p.m. ET to discuss the results. “Arrowhead continues to achieve strong execution in discovery, clinical and regulatory, and business development. Our pipeline has become quite mature, with four Arrowhead discovered candidates currently in pivotal Phase 3 s...

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the second quarter ending June 30, 2025. “The second quarter of 2025 marked an important inflection point for Rocket as we refined our strategic focus around our AAV cardiovascular gene therapy platform and took m...

PLANO, Texas--(BUSINESS WIRE)--QinFlow has launched its newest advanced fluid and blood warming solution to meet a critical need in hospital ORs and ICUs....

MENLO PARK, Calif.--(BUSINESS WIRE)--Apreo Health, a clinical-stage medical device company developing a novel treatment for severe emphysema, today announced the closing of an oversubscribed $130 million Series B financing round. The financing was co-led by new investors Bain Capital Life Sciences and Norwest, with participation from new investors F-Prime and Intuitive Ventures. Returning investors Lightstone Ventures and Santé Ventures also participated in the round. The Series B financing wil...